Chemoprevention and therapy of tea polyphenol of colorectal cancer in colorectal cancer rats and cells: a systematic review

doi:10.3760/cma.j.issn.1673-422X.2015.06.008

Abstract

Abstract: Objective To evaluate the chemoprevention and therapy of tea polyphenol of colorectal cancer in colon cancer rats and cells. Methods Such database as CBM, CNKI, VIP, Wanfang, PubMed, Medline, EMBase, Cochrane Library were searched for collecting the papers including using tea polyphenol as a therapy and chemoprevention of colorectal cancer in colorectal cancer rats and colorectal cells, from their establishment to June 1, 2014, and the references of those related papers were also searched by hand. After studying selection, assessment and data extraction were conducted by two reviewers. RevMan5.2 software was used for Meta-analyze. Results Seventeen studies were included. Three hundred and five rats and 5 colorectal cell lines were used to the research, they were divided into the study group (received the tea treatment) and the control group (not received the tea treatment). The results of metaanalyses showed that: ① Aberrant crypt foci (ACF): standardized mean difference SMD=-3.69(95%CI为-5.85～-1.54， Z=3.40, P=0.000 8), which indicated that tea polyphenol could reduce the number of ACF. ② The average number of tumors per rat: SMD=-0.83 (95%CI: -1.14～-0.51, Z=5.18, P=0.000 01), which indicated that tea polyphenol could reduce the average number of tumors per rat. ③ Cell cycle G1 phase: SMD=1.85(95%CI: 0.03～3.66, Z=1.99,P=0.05), which indicated that tea polyphenol could increase the cell in G1 phase. ④ Cell cycle S phase: SMD=-2.64(95%CI: -4.38～-0.90, Z=2.98, P=0.003), which indicated that tea polyphenol could decrease colon cancer cell in S phase. Conclusion Tea polyphenol has a positive effect on colon cancer cell and colon cancer rats.

Key words: Tea, Colorectal neoplasms, Cell cycle, Aberrant crypt foci

Liu Yuting, Qi Jian. Chemoprevention and therapy of tea polyphenol of colorectal cancer in colorectal cancer rats and cells: a systematic review[J]. Journal of International Oncology, 2015, 42(6): 430-435.

References

［1］ Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin3gallate (EGCG): mechanisms, perspectives and clinical applications［J］. Biochem Pharmacol, 2011, 82(12): 1807-1821. ［2］ Suganuma M, Ohkura Y, Okabe S, et al. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice［J］. J Cancer Res Clin Oncol, 2001, 127(1): 69-72. ［3］ Gupta S, Saha B, Giri AK. Comparative antimutagenic and anticlastogenic effects of green tea and black tea: a review［J］. Mutat Res, 2002, 512(1): 37-65. ［4］ Hu Y, McIntosh GH, Le Leu RK, et al. Combination of selenium and green tea improves the efficacy of chemoprevention in a rat colorectal cancer model by modulating genetic and epigenetic biomarkers［J］. PLoS One, 2013, 8(5): e64362. ［5］ Jia XD, Han C. Chemoprevention of tea on colorectal cancer induced by dimethylhydrazine in Wistar rats［J］. World J Gastroenterol, 2000, 6(5): 699-703. ［6］ Ju J, Liu Y, Hong J, et al. Effects of green tea and highfat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethaneinduced colon carcinogenesis mouse model［J］. Nutr Cancer, 2003, 46(2): 172178. ［7］ Ohishi T, Kishimoto Y, Miura N, et al. Synergistic effects of (-)epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane［J］. Cancer Lett, 2002, 177(1): 49-56. ［8］ Sengupta A, Ghosh S, Das S. Inhibition of cell proliferation and induction of apoptosis during azoxymethane induced colon carcinogenesis by black tea［J］. Asian Pac J Cancer Prev, 2002, 3(1): 41-46. ［9］ Xiao H, Hao X, Simi B, et al. Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethanetreated F344 rats［J］. Carcinogenesis, 2007, 29(1): 113-119. ［10］ Xu G, Ren G, Xu X, et al. Combination of curcumin and green tea catechins prevents dimethylhydrazineinduced colon carcinogenessi ［J］. Food Chem Toxicol, 2010, 48(1): 390-395. ［11］潘宏铭. 茶多酚对二甲肼诱发小鼠大肠肿瘤的抑制作用［J］. 中华预防医学杂志, 1995, 11(29): 356-360. ［12］银平章, 程书钧. 绿茶对实验性大肠癌抑制作用的研究［J］. 河南医学研究, 1995, 4(2): 164-167. ［13］ Lozano C, Juliá L, Jiménez A, et al. Electrontransfer capacity of catechin derivatives and influence on the cell cycle and apoptosis in HT29 cells［J］. FEBS Journal, 2006, 273(11): 2475-2486. ［14］ Saldanha SN, Kala R, Tollefsbol TO. Molecular mechanisms for inhibition of colon cancer cells by combined epigeneticmodulating epigallocatechin gallate and sodium butyrate［J］. Exp Cell Res, 2014, 324(1): 40-53. ［15］ SánchezTena S, AlcarrazVizán G, Marín S, et al. Epicatechin gallate impairs colon cancer cell metabolic productivity［J］. J Agric Food Chem, 2013, 61(18): 4310-4317. ［16］ Shimizu M, Deguchi A, Joe AK, et al. EGCG inhibits activation of HER3 and expression of cyclooxygenase2 in human colon cancer cells［J］. J Exp Ther Oncol, 2005, 5(1): 69-78. ［17］ Zhang X, Min KW, Wimalasena J, et al. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin3gallate［J］. J Cancer Res Clin Oncol, 2012, 138(12): 2051-2060. ［18］周芳. EGCG干预因子Ⅶa及PAR2-AP诱导SW620细胞增殖与迁移的作用探讨［D］. 镇江: 江苏大学, 2011. ［19］周萍. EGCG联合5-FU抑制结直肠癌HT-29细胞生长及其机制的实验研究［D］. 苏州: 苏州大学, 2008. ［20］蒋莎莉. 表没食子儿茶素没食子酸酯体外对人结直肠癌HT-29 细胞生长抑制作用及机制研究［D］. 衡阳: 南华大学, 2009. ［21］ Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings［J］. Cancer Lett, 1987, 37(2): 147-151. ［22］周鋆, 项平. 异常隐窝病灶研究进展［J］. 老年医学与保健, 2008, 14(6): 383-386. ［23］ Mori H, Yamada Y, Kuno T, et al. Aberrant crypt foci and betacatenin accumulated crypts; significance and roles for colorectal carcinogenesis［J］. Mutat Res, 2004, 566(3): 191-208. ［24］卢青, 陶珊, 陈琳, 等. 异常隐窝病灶与大肠肿瘤关系及发生途径的初步研究［J］. 中华消化内镜杂志, 2008, 25(10): 516-519. ［25］ Lambert JD, Lee MJ, Diamond L, et al. Dosedepdent levels of epigallocatechin3gallate in human colon cancer cell and mouse plasma and tissues［J］. Drug Metab Dispos, 2006, 34(1): 8-11. ［26］ Tan X, Hu D, Li S, et al. Differences of four catechins in cell cycle arrest and induction of apoptosis in LoVo cells［J］. Cancer Lett, 2000, 158(1): 1-6. ［27］张春霞. EGCG对LoVo和SW480结直肠癌细胞株的作用及对Notch1与Notch2基因表达的影响［J］. 世界华人消化杂志, 2011, 19(29): 3023-3027. ［28］ Lin CH, Chao LK, Hung PH, et al. EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumorinitiating cells through attenuation of STAT3 activation［J］. Int J Clin Exp Pathol, 2014, 7(5): 2372-2381. ［29］ Imai K, Suga K, Nakachi K. Cancerpreventive effects of drinking green tea among a Japanese population［J］. Prev Med, 1997, 26(6): 769-775.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[7]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[8]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[9]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[10]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[11]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[12]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[13]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[14]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[15]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.